Inventiva (NASDAQ:IVA) Stock Price Down 6.3% – Should You Sell?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) fell 6.3% during mid-day trading on Thursday . The company traded as low as $4.79 and last traded at $4.7810. 80,131 shares changed hands during trading, a decline of 81% from the average session volume of 431,862 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IVA shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research note on Tuesday, September 30th. Guggenheim cut their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. HC Wainwright raised their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Inventiva to a “hold” rating in a research report on Saturday, October 18th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.57.

Inventiva Stock Performance

The business has a 50-day moving average price of $4.30 and a 200-day moving average price of $4.45.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IVA. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Inventiva by 54.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares during the last quarter. Creative Planning bought a new position in Inventiva in the second quarter worth about $32,000. Millennium Management LLC bought a new position in Inventiva in the third quarter worth about $649,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Inventiva during the third quarter valued at about $116,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.